Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1837 1
1952 1
1956 1
1960 1
1961 1
1962 1
1964 2
1970 1
1973 1
1974 1
1977 7
1978 18
1979 11
1980 9
1981 8
1982 8
1983 16
1984 13
1985 16
1986 16
1987 16
1988 13
1989 11
1990 14
1991 12
1992 12
1993 20
1994 18
1995 19
1996 16
1997 15
1998 10
1999 11
2000 11
2001 16
2002 10
2003 9
2004 6
2005 13
2006 10
2007 12
2008 14
2009 17
2010 10
2011 12
2012 13
2013 11
2014 13
2015 22
2016 24
2017 16
2018 9
2019 11
2020 8
2021 18
2022 26
2023 14
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

626 results

Results by year

Filters applied: . Clear all
Page 1
[Gene therapy – from idea to reality].
Smith CIE, Blomberg P. Smith CIE, et al. Lakartidningen. 2017 Dec 19;114:EWYL. Lakartidningen. 2017. PMID: 29297925 Free article. Review. Swedish.
Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting.
Wiklander OP, Nordin JZ, O'Loughlin A, Gustafsson Y, Corso G, Mäger I, Vader P, Lee Y, Sork H, Seow Y, Heldring N, Alvarez-Erviti L, Smith CI, Le Blanc K, Macchiarini P, Jungebluth P, Wood MJ, Andaloussi SE. Wiklander OP, et al. Among authors: smith ci. J Extracell Vesicles. 2015 Apr 20;4:26316. doi: 10.3402/jev.v4.26316. eCollection 2015. J Extracell Vesicles. 2015. PMID: 25899407 Free PMC article.
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR. Naeem A, et al. Among authors: smith cie. Blood Adv. 2023 May 9;7(9):1929-1943. doi: 10.1182/bloodadvances.2022008447. Blood Adv. 2023. PMID: 36287227 Free PMC article.
Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies.
Rawls A, Diviak BK, Smith CI, Severson GW, Acosta SA, Wilson-Rawls J. Rawls A, et al. Among authors: smith ci. Biomolecules. 2023 Oct 17;13(10):1536. doi: 10.3390/biom13101536. Biomolecules. 2023. PMID: 37892218 Free PMC article. Review.
X-Linked Agammaglobulinemia.
Smith CIE, Berglöf A. Smith CIE, et al. 2001 Apr 5 [updated 2016 Aug 4]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2001 Apr 5 [updated 2016 Aug 4]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301626 Free Books & Documents. Review.
Therapeutic Oligonucleotides: State of the Art.
Smith CIE, Zain R. Smith CIE, et al. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:605-630. doi: 10.1146/annurev-pharmtox-010818-021050. Epub 2018 Oct 9. Annu Rev Pharmacol Toxicol. 2019. PMID: 30285540 Review.
Tec family kinases.
Yu L, Smith CI. Yu L, et al. Among authors: smith ci. FEBS J. 2011 Jun;278(12):1969. doi: 10.1111/j.1742-4658.2011.08135.x. Epub 2011 May 18. FEBS J. 2011. PMID: 21518256 Free article.
626 results